Biotech Values

[Praveen]

"The first stated reason for rejection—an insufficient number of patients—could presumably be rectified with data from the U.S. trial, but that trial is nearly two years from completion, so this is not an especially helpful solution."

And also the most important one. But the pharming deal you think seems like a long shot and might not put a floor on GTCB's price in the short term.

Praveen